Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A11 | P48066 | 4/20 | 0.35 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.31 |
| ▸ | SLC6A13 | Q9NSD5 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12824150 | 0.96 | SLC6A11 (0.34) | SLC6A11SLC6A1KIF11CYP1A2CYP3A4 | |
| SCHEMBL14319698 | 0.95 | SLC6A1 (0.33) | SLC6A11SLC6A1KIF11 | |
| SCHEMBL2820572 | 0.88 | SLC6A1 (0.34) | SLC6A11SLC6A1KIF11CYP1A2CYP3A4 | |
| SCHEMBL27050962 | 0.88 | SLC6A1 (0.34) | SLC6A11SLC6A1KIF11CYP1A2CYP3A4 | |
| SCHEMBL25764740 | 0.88 | SLC6A1 (0.34) | SLC6A11SLC6A1KIF11CYP1A2CYP3A4 | |
| SCHEMBL16329608 | 0.88 | SLC6A1 (0.34) | SLC6A11SLC6A1KIF11CYP1A2CYP3A4 | |
| SCHEMBL2472575 | 0.86 | SLC6A11 (0.35) | SLC6A11SLC6A1KIF11CYP1A2CYP3A4 | |
| SCHEMBL17166451 | 0.85 | ALDH1A1 (0.33) | SLC6A11CYP1A2CYP3A4MEN1TP53 | |
| SCHEMBL8332233 | 0.84 | ALDH1A1 (0.33) | SLC6A11SLC6A1CYP1A2CYP3A4ALDH1A1 | |
| SCHEMBL14005138 | 0.83 | KIF11 (0.32) | SLC6A11SLC6A1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 69 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218442-A1 | METHODS FOR INDEXING SAMPLES AND SEQUENCING MULTIPLE POLYNUCLEOTIDE TEMPLATES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2024-07-04 | — | — | US | disclosed |
| US-9999866-B2 | Preparation of templates for nucleic acid sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170145499-A1 | METHODS FOR INDEXING SAMPLES AND SEQUENCING MULTIPLE POLYNUCLEOTIDE TEMPLATES | ILLUMINA CAMBRIDGE LIMITED (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170145499-A1 | METHODS FOR INDEXING SAMPLES AND SEQUENCING MULTIPLE POLYNUCLEOTIDE TEMPLATES | ILLUMINA CAMBRIDGE LIMITED (US) | 2017-05-25 | — | — | US | disclosed |
| US-20170021325-A1 | Preparation of Templates for Nucleic Acid Sequencing | SOLEXA LIMITED (GB) | 2017-01-26 | — | — | US | disclosed |
| US-20170021325-A1 | Preparation of Templates for Nucleic Acid Sequencing | SOLEXA LIMITED (GB) | 2017-01-26 | — | — | US | disclosed |
| US-9512478-B2 | Methods for indexing samples and sequencing multiple polynucleotide templates | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-12-06 | — | — | US | disclosed |
| US-9512478-B2 | Methods for indexing samples and sequencing multiple polynucleotide templates | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-12-06 | — | — | US | disclosed |
| US-9498763-B2 | Preparation of templates for nucleic acid sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-11-22 | — | — | US | disclosed |
| US-9498763-B2 | Preparation of templates for nucleic acid sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2016-11-22 | — | — | US | disclosed |
| US-20090233802-A1 | Methods for indexing samples and sequencing multiple polynucleotide templates | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-09-17 | — | — | US | disclosed |
| US-20090118128-A1 | Preparation of templates for nucleic acid sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2009-05-07 | — | — | US | disclosed |
| US-20090118128-A1 | Preparation of templates for nucleic acid sequencing | ILLUMINA CAMBRIDGE LIMITED (GB) | 2009-05-07 | — | — | US | disclosed |
| US-20090088327-A1 | Method for sequencing a polynucleotide template | SOLEXA LIMITED (GB) | 2009-04-02 | — | — | US | disclosed |
| US-20090088327-A1 | Method for sequencing a polynucleotide template | SOLEXA LIMITED (GB) | 2009-04-02 | — | — | US | disclosed |
| WO-2008093098-A2 | METHODS FOR INDEXING SAMPLES AND SEQUENCING MULTIPLE NUCLEOTIDE TEMPLATES | ILLUMINA CAMBRIDGE LIMITED (GB) | 2008-08-07 | — | — | WO | disclosed |
| WO-2008041002-A2 | METHOD FOR SEQUENCING A POLYNUCLEOTIDE TEMPLATE | ILLUMINA CAMBRIDGE LIMITED (GB) | 2008-04-10 | — | — | WO | disclosed |
| US-20080009420-A1 | Isothermal methods for creating clonal single molecule arrays | SOLEXA INC. | 2008-01-10 | — | — | US | disclosed |
| WO-2007107710-A1 | ISOTHERMAL METHODS FOR CREATING CLONAL SINGLE MOLECULE ARRAYS | SOLEXA LIMITED (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007010251-A2 | PREPARATION OF TEMPLATES FOR NUCLEIC ACID SEQUENCING | SOLEXA LIMITED (GB) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118128-A1 | Preparation of templates for nucleic acid sequencing | RNGTT, POLRMT, POLM | SLC6A11 4807/4885SLC6A1 4778/4885KIF11 1305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.